Viridian Therapeutics announces promising Phase 1 results for VRDN-008
Viridian Therapeutics announced positive results from a Phase 1 trial showing VRDN-008, a half-life extended FcRn inhibitor, achieved 74% IgG reduction with an 8-week dosing interval, supporting a potential best-in-class profile for autoimmune diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed